BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Chesapeake PERL, Inc. to Produce Nerve Agent Bioscavenger for DTRA


10/25/2012 10:21:41 AM

SAVAGE, Md., Oct. 24, 2012 -- SAVAGE, Md., Oct. 24, 2012 /PRNewswire/ -- Chesapeake PERL has been awarded a contract to develop the human nerve agent bioscavenger butyrylcholinesterase (BChE) as a potential nerve agent countermeasure for the Defense Threat Reduction Agency (DTRA). The contract will fund development of a recombinant human BChE and its production in C-PERL's PERLXpress high efficiency protein manufacturing system. C-PERL will collaborate with the US Army Medical Research Institute of Chemical Defense (located on the Aberdeen Proving Grounds, MD) to test the circulatory stability and anti-nerve agent protective efficacy of the recombinant BChE, with the ultimate objective of advancing a product into human clinical trials.

BChE is the lead bioscavenger candidate based on its ability to afford protection over a broad range of highly toxic organophosphorus nerve agents. It is a natural mammalian blood protein that can be administered either prophylactically or post-exposure, but is normally present at low concentrations in human plasma making it both expensive to produce and severely limited in supply. DTRA is seeking economical alternative production methods utilizing recombinant technology, and has selected C-PERL for its experience in manufacturing high quality proteins using its highly automated, efficient and cost-effective PERLXpress production system.

Chesapeake PERL is a biological manufacturer specializing in the production of high quality proteins, including glycosylated and lipid-associated proteins, multimeric forms and self-assembling macromolecular structures. PERLXpress, the Company's proprietary, highly automated in vivo implementation of the Baculovirus Expression Vector System, employs whole insect larvae as mini-bioreactors. The tissue heterogeneity of the insect bioreactors leads to very high levels of protein expression as well as protein modification and processing that closely resemble native versions of the same proteins, and the system flexibility enables rapid, precisely controlled production from micrograms to tens of grams of protein. www.c-perl.com.

Contact: Dr. George Buchman - 301-317-9300 x104 - gbuchman@c-perl.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES